Pfizer/BioNTech COVID-19 Vaccine's Positive Advisory Committee Complicated By Pediatric Issues

 
• By Sarah Karlin-Smith

US FDA expected to quickly clear the first emergency use authorization for a COVID-19 vaccine following 17-4 VRBPAC vote, but a disorganized committee ending made it unclear why some members voted no. Pediatric data was at issue for at least two voters, though.

Five advisory committee members opted not to endorse Pfizer's vaccine, but they didn't get a chance to explain why. • Source: illustration based on committee slide

More from US FDA Performance Tracker

More from Regulatory Trackers